Zymeworks Inc.
NASDAQ:ZYMEBiotechnology
-$0.38 today
- Market cap
- $1.80B
- Beta
- 1.14
- P/E (TTM)
- -16.6
- EPS (TTM)
- -$1.37
Volume 0.57M
Average 0.71M
ZYME EBITDA Margin
EBITDA as a percentage of revenue.
Zymeworks Inc.NASDAQ: ZYME
EBITDA Margin · Q3 FY2026 · quarter ended Sep 2026
EBITDA Margin widens to 70.8%
EBITDA Margin was 70.8% in Q3 FY2026, up 127.6 pp from a year earlier. On a trailing-twelve-month basis it was 21.5%, up 61.6 pp year over year. Over 3 fiscal years it narrowed by 99.3 pp.
Context
- EBITDA Margin widened in 2 of the last 3 fiscal years.
What to watch
Whether EBITDA Margin reaches the consensus estimate from 8 analysts of 45.1% for the fiscal year ending Dec 2026, up from -64.8% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterSep 2026
- 70.8%+1015.0 pp QoQ
- Last fiscal yearDec 2025
- -64.8%+77.6 pp YoY
- LTMSep 2026
- 21.5%+61.6 pp YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- -64.8%
- Year-over-year change
- +77.6pp
| Period | Period end | EBITDA Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | -64.8% | +77.6pp |
| FY2024 | 2024-12-31 | -142.4% | +16.4pp |
| FY2023 | 2023-12-31 | -158.8% | -193.3pp |
| FY2022 | 2022-12-31 | 34.5% | +807.0pp |
| FY2021 | 2021-12-31 | -772.4% | — |
EBITDA Margin vs competitors
How ZYME compares with its peers on the latest reported figures
- ZYME's LTM Sep 2026 EBITDA Margin of 21.5% is the 3rd highest of the 10 companies compared; the peer median is -117.7%.
- Its year-over-year change of +61.6 pp is the 3rd highest of 9, against a peer median of -26.5 pp.
- Over three fiscal years its change of -99.3 pp compares with a peer median of +89.7 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Mar 2026 | 48.0% | +82.8 pp | +491.0 pp | |
| LTM Aug 2026 | 46.0% | +315.4 pp | +147.4 pp | |
| LTM Sep 2026 | 21.5% | +61.6 pp | -99.3 pp | |
| LTM Mar 2026 | -32.2% | -1.2 pp | +32.0 pp | |
| LTM Mar 2026 | -105.1% | +22.1 pp | -58.4 pp | |
| LTM Jun 2026 | -117.7% | -51.9 pp | -9.6 pp | |
| LTM Mar 2026 | -162.2% | -191.7 pp | +161.5 pp | |
| LTM Mar 2026 | -1336.8% | — | +61547.4 pp | |
| FY2025 | -3017.4% | -1343.3 pp | — | |
| LTM Sep 2026 | -272652.7% | -264146.9 pp | -12607.1 pp | |
| FY2025 | — | — | — | |
| Peer median (excluding ZYME) | -117.7% | -26.5 pp | +89.7 pp | |
Competitors are the stored peer set for ZYME. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 26.68M | 412.48M | 76.01M | 76.3M | 105.97M |
| Cost of Revenue | 0 | 0 | 142.99M | 0 | 0 |
| Gross Profit | 26.68M | 412.48M | (66.98M) | 76.3M | 105.97M |
| Gross Margin | 100.0% | 100.0% | -88.1% | 100.0% | 100.0% |
| Research & Development | 199.75M | 208.6M | 143.62M | 134.62M | 137M |
| Selling, General & Admin | 42.6M | 73.4M | 70.4M | 61.5M | 61.5M |
| Operating Expenses | 242.31M | 281.95M | 71.08M | 213.41M | 198.5M |
| Depreciation & Amortization | 9.58M | 12M | 17.31M | 11.19M | 11.11M |
| EBITDA | (206.09M) | 142.49M | (120.7M) | (108.62M) | (68.64M) |
| EBITDA Margin | -772.4% | 34.5% | -158.8% | -142.4% | -64.8% |
| Operating Income | (215.63M) | 130.53M | (138.05M) | (137.11M) | (92.54M) |
| Operating Margin | -808.2% | 31.6% | -181.6% | -179.7% | -87.3% |
| Interest Income | 1.97M | 3.6M | 19.71M | 19.94M | 13.35M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 3.27M | 4.71M | 18.81M | 20.5M | 12.78M |
| Income Before Tax | (212.36M) | 135.23M | (119.24M) | (116.61M) | (79.75M) |
| Pre-Tax Margin | -795.9% | 32.8% | -156.9% | -152.8% | -75.3% |
| Income Tax Expense | (516K) | 10.89M | (568K) | 6.08M | 1.38M |
| Net Income | (211.84M) | 124.34M | (118.67M) | (122.7M) | (81.13M) |
| Net Margin | -794.0% | 30.1% | -156.1% | -160.8% | -76.6% |
| EPS (Basic) | (4.06) | 1.91 | (1.72) | (1.62) | (1.08) |
| EPS (Diluted) | (4.61) | 1.90 | (1.72) | (1.62) | (1.08) |
| Weighted Avg Shares | 52.13M | 65.19M | 68.86M | 75.85M | 75.34M |
| Weighted Avg Shares (Diluted) | 52.13M | 65.25M | 68.86M | 75.88M | 75.34M |
Zymeworks Inc.
NASDAQ:ZYME
Intrinsic Alpha fair value
Locked
Current Price
$25.84
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.